BFLY · Butterfly Network, Inc.

The new AI-powered tool determines how far along a pregnancy is in minutes—providing critical information to guide timely care and help reduce maternal and fetal mortality worldwide. Butterfly Network, Inc. (“Butterfly,” “the Company”) (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound solution. This marks the first FDA-cleared blind-sweep ultrasound AI tool for estimating gestational age. Butterfly Network received FDA clearance for a fully automated Gestational Age Tool integrated into its handheld ultrasound solution. Despite its critical importance in guiding pregnancy care, timely, accurate gestational age assessment remains a gap in maternal care worldwide. In the U.S., nearly half of rural counties lack hospital obstetric services, and

Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company’s proprietary semiconductor platform through co-development, licensing, and strategic collaborations with organizations developing novel ultrasound-enabled technologies. The program allows partners to integrate Butterfly’s core ultrasound technology into new products and applications, expanding its impact beyond the

Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “Our fourth quarter 2025 performance shows that our strategy is taking hold and our vision is becoming tangible. We delivered record quarterly revenue of $31.5 million, growing 41% year over year, and achieved the first quarter of positive operating cash flow in

Butterfly Network, Inc . (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced that it will participate at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman; John Doherty, EVP, Chief Financial Officer; and Megan Carlson, SVP, Accounting & Finance – Chief Accounting Officer, will present and host one-on-one investor meetings. The company presentation will occur at 11:50 AM ET on March 3. A webcast of the presentation will be available in the Events & Presentations section of the Butterfly investor website ( https://ir.butterflynetwork.com/events-and-presentations ). To schedule a one-on-one meeting with Butterfly management, please reach out to your TD Cowen representative. About Butterfly Network Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in

Butterfly is now authorized to sell cloud services to all state and local government agencies, including the state of Texas. Butterfly Network, Inc . (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced that its Butterfly iQ+/iQ3 and Compass AI™ ultrasound solution have achieved GovRAMP and TX-RAMP Authorizations. The certifications authorize the Company to sell cloud services to all state and local government agencies, including in the state of Texas. GovRAMP (formerly StateRAMP), a nationally recognized risk authorization management program, provides a standardized approach to assessing cloud products. Achieving GovRAMP Authorization demonstrates Butterfly's dedication to meeting the highest security and compliance standards, ensuring the trust and confidence of government agencies and organizations. In addition, the company has secured TX-RAMP Certification for the

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on February 26 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations . Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time: United States (Local): +1 646 844 6383 United States (Toll-Free): +1 833 470 1428 Global

The company will present a business update at the 44th J.P. Morgan Healthcare Conference on January 15, 2026 at 9:00 am PST. Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the fourth quarter ended December 31, 2025 of at least 17% year over year. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “We enter 2026 with strong momentum and continued growth in our handheld ultrasound business. That foundation gives us confidence as we continue to scale our core commercial business, while evolving Butterfly as a differentiated Ultrasound-on-Chip™ and semiconductor company. As we expand co-development and chip licensing opportunities, 2026 represents a meaningful inflection year for the company – one I’ll begin to outline at the J.P. Morgan conference

Planned API release will, for the first time, allow third-party access to Butterfly’s digital 3D beam steering capabilities – enabling development of advanced AI-enabled image acquisition tools. Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the company”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced plans to release its Beam Steering API for advanced third-party AI application and technology development within the company’s Butterfly Garden™ and Ultrasound-on-Chip™ co-development programs. The new API release, expected in the first half of 2026, will open access to core capabilities that were previously reserved for the company’s own app, like iQ Slice™ and iQ Fan™. The basis of the Beam Steering API is Butterfly’s electronically steered 3D imaging software, including off-axis beam tilt of up to 20 degrees. The technology can support advanced applications that reduce reliance on precise probe positioning,